Cost-Effective Therapy for Multiple Myeloma
A recent analysis showed which therapy option as the most cost-effective in pretreated multiple myeloma?
A. Daratumumab monotherapy
B. Pomalidomide plus dexamethasone
C. Carfilzomib monotherapy
D. Lenalidomide plus dexamethasone
Researchers reported that the use of pomalidomide plus low-dose dexamethasone yielded comparable life-years and quality-adjusted life years gained with daratumumab and carfilzomib as well as lower or comparable costs than daratumumab (-$8,919) and carfilzomib (-$195). To read the full study, click here.